Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OBI PharmaROCO:4174 -2.72%45 Days Inventory is 55.33 as of Dec. 2025, which is 27% below its 10-year median of 75.99. GuruFocus rates ROCO:4174 with a GF Score™ of 45/100 and a GF Value™ of NT$138.67 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 638 Biotechnology companies, OBI Pharma ranks better than 80.25% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). OBI Pharma's Average Total Inventories for the
three
months ended in Dec. 2025 was NT$22.25 Mil. OBI Pharma's Cost of Goods Sold for the
three
months ended in Dec. 2025 was NT$36.69 Mil.
Hence, OBI Pharma's Days Inventory for the
three
months ended in Dec. 2025 was 55.33.
The historical rank and industry rank for OBI Pharma's Days Inventory or its related term are showing as below:
ROCO:4174'
s Days Inventory Range Over the Past 10 Years
Min: 61.89 Med: 75.99 Max: 326.07
Current: 70.19
During the past 13 years, OBI Pharma's highest Days Inventory was 326.07. The lowest was 61.89. And the median was 75.99.
ROCO:4174's Days Inventory is ranked better than 80.25% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs ROCO:4174: 70.19
OBI Pharma's Days Inventory
declined
from Dec. 2024 (72.99) to Dec. 2025 (55.33).
Inventory Turnover measures how fast the company turns over its inventory within a year.
OBI Pharma's Inventory Turnover for the
three
months ended in Dec. 2025 was 1.65.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
OBI Pharma's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 1.07.
OBI Pharma (ROCO:4174) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
OBI Pharma's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
OBI Pharma's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
OBI Pharma Days Inventory Related Terms
OBI Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for OBI Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4174 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, OBI Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OBI Pharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OBI Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where OBI Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OBI Pharma (ROCO:4174) has a Days Inventory of 55.33 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on OBI Pharma and its competitors. This is 27% below median its historical median of 75.99. Over the past decade, OBI Pharma's Days Inventory has ranged from 61.89 to 326.07. According to the industry distribution chart, OBI Pharma ranks #126 out of 638 companies in the Biotechnology industry, placing it in the top 19.7%.
Is OBI Pharma's Days Inventory too high?
OBI Pharma's current Days Inventory of 55.33 is 27% below median its 10-year median of 75.99. Over the past 10 years, this metric has ranged from a low of 61.89 to a high of 326.07. The Biotechnology industry median Days Inventory is 183.20. OBI Pharma's value of 55.33 is 69.8% below this industry median. Based on the distribution chart, OBI Pharma ranks #126 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OBI Pharma has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OBI Pharma ranks #126 out of 638 companies for Days Inventory. This places OBI Pharma in the top 20% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.20. OBI Pharma's value of 55.33 is 69.8% below this benchmark. Historically, OBI Pharma's own Days Inventory has ranged from 61.89 to 326.07 over the past decade. While the company's 10-year median is 75.99 vs. the industry median of 183.20, OBI Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OBI Pharma's current Days Inventory of 55.33 is 69.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on OBI Pharma and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OBI Pharma's current Days Inventory is 55.33, which is 27% below median its own 10-year median of 75.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.67, compared to a current price of NT$28.65 — trading 79.3% below its estimated fair value. The current Days Inventory is 55.33, which is 27% below median its 10-year median of 75.99 and 69.8% below the Biotechnology industry median of 183.20. OBI Pharma's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current Days Inventory is 55.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OBI Pharma (ROCO:4174) Overvalued in 2026?
Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued.
The current stock price of NT$28.65 is trading 79.3% below its estimated GF Value™ of NT$138.67.
GuruFocus considers OBI Pharma to be Possible Value Trap.
Key valuation signals for ROCO:4174:
Days Inventory: 55.33 (27% below median its 10-year median of 75.99)
GF Value™: NT$138.67 vs. price of NT$28.65 (79.3% below fair value)
Industry Position: 69.8% below the Biotechnology median (#126 of 638)
No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
45GF Score
Get the complete analysis for ROCO:4174
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4174 has been successfully added to your 
